anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:The titled preventive or remedy that contains tripsin inhbitor in human urine, as an active ingredient. CONSTITUTION:Human urine tripsin inhibitor (UTI) is used as an active ingredient, to give a preventive or remedy for diseases caused by amylase and/or lipase activity exasperation. The UTI, as the active ingredient, is a glycoprotein of 17,000-70,000 molecular weight and obtained from human urine by purification. Namely, human urine is concentrated, passed through an arginine-cephalose column, then the column is eluted with 2% aqueous ammonia containing 0.2M NaCl. Then, the eluate is subjected to gel chromatography wth a Sephadex G-100 column to collect the UTI fraction. The product is effective in prevention and treatment for pimelosis, adiposis, lipoidosis, diabetes or arteriosclerosis. The dosage is 10,000-1,000,000 units/day and it is given orally, rectally or by injection or inhalation.
NEW MATERIAL:A compound of formula I (R1 is H, lower alkyl, aryl, aralkyl; R2 is H, lower alkyl, aryl, aralkyl). EXAMPLE:6-Fluoro-2,7,7,8,8-pentamethyl-2,4-diazabicyclo[4,2,0]octane-3 ,5-dione. USE:It has a strong activity of inducing cancer cell differentiation and can be used as an excellent chemical therapeutic agent for cancer. Low toxicity. PREPARATION:The photoaddition reaction of a uracil of formula II to 2,3- dimethyl-2butene (tetramethylethylene) gives the compound of formula I. The photoaddition reaction is carried out using 1 mole to several-ten moles of 2,3- dimethyl-2-butene per mole of the compound of formula II, preferably at a molar ratio of 10/1-12/1, in an organic solvent.
Significant drug interactions with lamotrigine are summarized in Table 13. Additional details of these drug interaction studies are provided in the Clinical Pharmacology section [see CLINICAL PHARMACOLOGY (12.3)] . 

Effect of Lamotrigine on Organic Cationic Transporter 2 Substrates

Lamotrigine is an inhibitor of renal tubular secretion via organic cationic transporter 2 (OCT2) proteins [see Clinical Pharmacology ( CLINICAL PHARMACOLOGY (12.3)].)] . This may result in increased plasma levels of certain drugs that are substantially excreted via this route. Coadministration of lamotrigine with OCT2 substrates with a narrow therapeutic index (e.g., dofetilide) is not recommended.
Highly interactive, HIV prevention skills-based group intervention in 6 sessions. Tailored to YMSM.
Described are synthetic constructs comprising a linear core chain having two or more side chains pending directly from different points on the linear core chain.  Each of the side chains comprises an epitopic site of an antigen or a peptide.  The synthetic constructs are monomeric units that can be linked together or polymerised to form a polymer.  In this feature the epitopic sites of the side chains may be the same or different.  The linear core chain may be a linear sequence of amino acids having two or more of the same peptide pending directly from different points on the linear sequence.  Another aspect concerns a support having one or more of the aforementioned synthetic constructs or polymers coupled thereto.  Another embodiment is directed to antibodies raised against the synthetic constructs or polymers.  The antibodies can be purified using the aforementioned supports.  Also described is a vaccine comprising the aforementioned synthetic constructs.  Methods for synthesizing the constructs and polymers are also included. In Fig.1, a monomer (100) is depicted having a linear core chain (102) with side chains (104) pending therefrom.  Functional group X and functional group Y are related in that they are capable of reacting with one another to form a covalent bond and thereby link two or more monomers to form a polymer (120) as depicted in Fig. 2. The functional groups may be selected from those described above, e.g., in conjunction with the definition of a monomer.  The monomers may be the same or different.  When the monomers are different, the differences can reside in the composition of linear core chain (102) or side chains (104), or both.
Patients will receive 68Ga-HBED-CC-PSMA PET / CT imaging for the detection of prostate cancer recurrence sites. This determination will be made at the "patient" and "lesion" level by reference to the gold standard (or truth standard) that will be obtained from the histology data and / or from an imaging and evolution follow-up. PSA over a period of at least 6 months (RECIST 1.1 criteria).
Subjects received a single oral dose of 10 mg loratadine-oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in treatment period 1, followed by a single oral dose of 10 mg loratadine-claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in treatment period 2. A wash-out period of at least 10 calendar days was maintained between the 2 treatments.
Pulmonary fibrosis is an often fatal lung disease. Immune cells such as macrophages were shown to accumulate in the fibrotic lung, but their contribution to the fibrosis development is unclear. To recapitulate the involvement of macrophages in the development of pulmonary fibrosis, we developed a fibrotic microtissue model with cocultured human macrophages and fibroblasts. We show that profibrotic macrophages seeded on topographically controlled stromal tissues became mechanically activated. The resulting co-alignment of macrophages, collagen fibers, and fibroblasts promoted widespread fibrogenesis in micro-engineered lung tissues. Anti-fibrosis treatment using pirfenidone disrupts the polarization and mechanical activation of profibrotic macrophages, leading to fibrosis inhibition. Pirfenidone inhibits the mechanical activation of macrophages by suppressing integrin αMβ2 and Rho-associated kinase 2. These results demonstrate a potential pulmonary fibrogenesis mechanism at the tissue level contributed by macrophages. The cocultured microtissue model is a powerful tool to study the immune-stromal cell interactions and the anti-fibrosis drug mechanism.
Hemorrhage due to trauma is one of the leading causes of morbidity and mortality worldwide in both the civilian and military settings. A major factor contributing to death and disability from severe blood loss is poor tissue perfusion and oxygenation of the vital organs. Traditionally, protection of absolute cerebral blood flow (CBF) has been deemed the most important factor in maintaining perfusion and oxygenation. In recent years, it has been shown that low frequency (LF, \~0.1 Hz) pulsatile CBF is associated with increased tolerance to simulated hemorrhage in healthy human subjects, despite ≥30% reductions in absolute CBF. The underlying mechanism for this improvement in tolerance is unclear; the proposed study aims to address this knowledge gap. The central hypothesis is that LF oscillations (\~0.1 Hz) will improve CBF and tissue oxygenation under hypoxic and/or hypovolemic conditions, due to increased shear stress and the release of vasoactive mediators that facilitate vasodilation and enhanced tissue perfusion. This hypothesis will be addressed in two Specific Aims under hypoxic and hypovolemic conditions: 1) determine if inducing oscillations in arterial blood pressure and CBF at 0.1 Hz elicits shear stress-induced vasodilation, subsequently increasing CBF and oxygenation; and, 2) assess the effect of 0.1 Hz oscillations on the release of shear stress-induced vasoactive mediators. Twenty human subjects (males and females) will be recruited to address these aims using oscillatory lower body negative pressure (OLBNP) to induce 0.1 Hz oscillations. Measurements will include CBF (intracranial \& extracranial arteries), shear stress, cerebral oxygenation, arterial pressure, and venous blood samples for assessment of nitric oxide, prostaglandin E2, 6-keto-PGF1α (a metabolite of prostacyclin, PGI2), histamine, and endothelin-1. The rationale for the proposed research is to identify a mechanism for the previously observed increase in tolerance to simulated hemorrhage with increases in LF oscillations in arterial pressure and CBF. The approach is innovative as it challenges the traditional association of hemodynamic variability with negative clinical outcomes using a novel methodological approach in human subjects. This contribution is significant as the findings may provide an alternative approach to maintaining cerebral perfusion and oxygenation under conditions of hypovolemia and/or hypoxia.
The primary intervention will be setting the FDA-approved Certas Plus with Siphonguard, programmable CSF shunt valve to active (open shunt group)(setting 4)(110 mm H2O) or placebo (closed shunt group)(setting 8)(\>400 mm H2O)in a 1:1 ratio. By the time of the primary objective evaluation at four months, the closed shunt group will have zero months of active treatment, and the open shunt group will have four months of active treatment. At four months, shunts for subjects in the closed shunt group will be adjusted to setting 4. To maintain blinding, all patients will be adjusted/ mock adjusted to the active setting in a similar fashion. Patients from both groups will not be adjusted before four months of active treatment, unless judged medically necessary by the treating team. Following four months of active treatment, all subjects in each group will have shunt adjustments according to clinical standards at each center.
Deficits in corneal innervation lead to neurotrophic keratopathy (NK). NK is frequently associated with facial palsy, and corneal damage can be accelerated by facial palsy deficits. Corneal nerves are important regulators of limbal stem cells, which play a critical role in epithelial maintenance and healing. Nonsurgical treatments of NK have undergone recent innovation, and growth factors implicated in corneal epithelial renewal are a promising therapeutic avenue. However, surgical intervention with corneal neurotization (CN) remains the only definitive treatment of NK. CN involves the transfer of unaffected sensory donor nerve branches to the affected cornea, and a variety of donor nerves and approaches have been described. CN can be performed in a direct or indirect manner; employ the supraorbital, supratrochlear, infraorbital, or great auricular nerves; and utilize autograft, allograft, or nerve transfer alone. Unfortunately, comparative studies of these factors are limited due to the procedure's novelty and varied recovery timelines after CN. Regardless of the chosen approach, CN has been shown to be a safe and effective procedure to restore corneal sensation and improve visual acuity in patients with NK.
INTRODUCTION: Bariatric surgery improves many obesity-related comorbidities, yet the literature remains inconclusive on the impact of bariatric surgery on asthma. Our primary objective was to identify the long-term impact of bariatric surgery on asthma severity and medication use.
METHODS: A retrospective review was completed of all patients with a diagnosis of asthma who underwent bariatric surgery over 10 years at a single institution. Primary outcomes were the number of asthma medications prescribed at five time points (preoperative, postoperative < 18 months, 19-36 months, 37-60 months, 60 + months) after bariatric surgery. Secondary outcomes were spirometry results and BMI.
RESULTS: There were 260 patients with 84.6% female predominance. There were 168 sleeve gastrectomy patients and 92 Roux-en-Y gastric bypass patients. Mean age was 47.6 ± 10.7 years, mean BMI was 46.0 ± 6.8 kg/m2, and 54.2% were previous tobacco users. The total number of patients on two or more asthma medications decreased from 46% preoperatively to 41% at 18 months, to 36% at 36 months, and to 32% at 60 months after surgery. The total number of patients free from asthma medication increased from 25% preoperatively to 33% at 60 months postoperatively. Asthma medication use decreased in both surgery groups, and neither operation demonstrated superiority. No significant improvement nor differences were found between groups at any time point regarding FEV1/FVC ratio spirometry measures.
CONCLUSION: Bariatric surgery reduces the use of medications taken for management of asthma. The amount of asthma medication usage decreases with time and is sustained at 60 months after bariatric surgery.
Bioimpedance spectroscopy used along with arm measurements. Patients undergo arm circumference measurement and bioimpedance spectroscopy at 4, 10, 16, 22, 28, and 34 months.
Hydrophilic polyurethane polymers having carboxy groups in the polymer backbone are prepared by reacting a polyol component, an ester of a carboxylic acid and a polyisocyanate to form a polyurethane intermediate. The intermediate is then saponified and the saponified product neutralized to form free carboxy groups. The water absorption of the intermediates and saponified polymers is above 10% and the polyurethanes may range from rigid solids to gel-like, high water absorptive polymers. Neutralization of the carboxy group with ammonium hydroxide produces a water soluble polyurethane which becomes water insoluble when the ammonia is driven off. The carboxy groups introduced into the polymeric chain provide reactive sites for attachment of various side-groups and also allow for various curing procedures. The polymers exhibit excellent adhesion to various substrates, and are suitable for use as light sensitive photographic layers on films, paper or glass; as boat and pipe coatings for decreasing hydrodynamic drag; as drug delivery systems; as burn and wound dressings; in cosmetic applications; in body implants; as coatings on cannulae; and a host of other applications.
Laparoscopic hysterectomy is one of the most common gynecologic surgeries worldwide. Generally, in total laparoscopic hysterectomy (TLH), uterine arteries are coagulated or transected close to the uterus, alongside the cervix, like surgical technique of a conventional total abdominal hysterectomy. Recently, several studies showed that ligation of uterine artery where it originates from the internal iliac artery during TLH (so-called "retroperitoneal TLH") is effective for reducing blood loss. However, the application of this technique to clinical practice have not been well investigated in terms of its efficacy and safety. Moreover, most of the previous studies on retroperitoneal TLH were small case series or retrospective comparative studies with conventional TLH. Therefore, the investigators conducted this randomized trial to investigate the role of retroperitoneal TLH in enlarge uterus.
A pathological increase in intestinal leak is implicated in age-associated muscle loss, termed sarcopenia, and reduced sarcopenia-related quality-of-life (SarQoL). However, the potential therapies remain elusive. We investigated the effects of probiotic supplementation on sarcopenia and SarQoL in geriatric older adults. We randomized sarcopenic men into placebo (age = 71.4 ± 3.9 years, n = 63) and probiotic (age = 73 ± 4.1 years, n = 60) groups for 16 weeks. The probiotic used was one capsule daily of Vivomix 112 billion for 16 weeks. We measured sarcopenia parameters of handgrip strength (HGS) and skeletal mass index (SMI), plasma zonulin (marker of the intestinal leak), and SarQoL using a targeted questionnaire. Probiotics improved the SarQoL scores for locomotion, functionality, and activities of daily living and prevented a decline in cumulative SarQoL observed in the placebo group (all p < 0.05). Probiotic supplementation also reduced plasma zonulin and marker of systemic bacterial load. These changes were accompanied by an increase in HGS and maintenance of gait speed in the probiotic group compared to the placebo group. Correlation analysis revealed significant associations of cumulative SarQoL scores with plasma zonulin and HGS in the probiotic group. Collectively, probiotics improved SarQoL and HGS by repairing pathological intestinal leak. Future studies may further dissect the relation between intestinal leak and SarQoL in older adults taking probiotics.
Multiple Sclerosis (MS) is a chronic, progressive inflammatory disorder of the central nervous system. It is caused by loss of myelin, the outer protective layer of the neuron, resulting in a disruption of the signal potentials that flow through the neurons. This can lead to a variety of sensory, visual, and motor disturbances. MS affects almost 1 million people in the United States with the prevalence being two to three times higher in women than in men. Over 80% of MS patients suffer from lower urinary tract symptoms, with OAB and urinary incontinence (UI) being the predominant bladder dysfunctions. OAB is characterized by sudden feeling of urgency, frequent urination, and urge incontinence. PTNS is an FDA approved treatment for OAB and is recommended as third line treatment for OAB by the American Urological Association (AUA) and Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU). However, it is not approved for MS and as such these treatments are not covered by insurance.

Here the investigators propose a pilot, double blind, randomized, sham-controlled trial to assess the benefit of PTNS in treating OAB symptoms in MS patients. The data generated by this study would provide support for a future multi-institutional, randomized prospective trial.
The invention provides a polypeptide, the amino acid sequence of which is shown as SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 or SEQ ID NO. 6; or contains a functional amino acid sequence shown as SEQ ID NO.3 or SEQ ID NO. 6. The invention also provides application of the polypeptide or the salt thereof in preparing a medicament for treating or preventing tumors. The invention also provides application of the polypeptide or the salt thereof in preparing a medicament for promoting cancer cells to be sensitive to chemotherapy. The invention also provides application of the polypeptide or the salt thereof and a chemotherapeutic drug in combination in preparing drugs for treating tumors. The polypeptide or the polypeptide derivative can be specifically combined with USP25, inhibit the interaction between USP25 and SHLD2, inhibit DNA damage repair and further improve the sensitivity of tumor cells to chemotherapeutic drugs. The combination of the polypeptide and the chemotherapeutic drug of the invention significantly promotes the tumor cell killing effect mediated by chemotherapy in vivo and in vitro.
FIELD: medicine, oncology, pharmacy. SUBSTANCE: invention relates to pharmaceutical composition inhibiting growth of malignant neoplasms and tumors in mammals, in part, in humans and warm-blooded animals and method of treatment of cancer patients. Composition shows efficiency against viruses also. Composition has N-chlorophenylcarbamates and N-chlorophenyl-thiocarbamates that are systemic herbicides. Composition can include except for N-chlorophenylcarbamates and N-chloro- phenylthiocarbamates also chemotherapeutic agents and, optionally, potentiating agent. Invention describes also the composition for treatment of animals and humans with viral infections that includes effective amount of N- chlorophenyl-carbamates and N-chlorophenylthiocarbamates and potentiating agent. Composition shows effect without action or with mild action on normal cells. EFFECT: enhanced effectiveness of composition, valuable anticancer and antiviral properties. 17 cl, 2 tbl
OBJECTIVE: To investigate the -75 G/A single-nucleotide polymorphism in the promoter region of apolipoprotein A1 gene (apoA1) and its association with gestational diabetes mellitus (GDM) in pregnant women and to provide references for the exploration in the molecular genetic basis of GDM.
METHODS: A total of 626 GDM patients and 1022 normal pregnant women, ie, the controls, were included in the study. The genotyping of apoA1 -75 G/A polymorphism was performed by polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) analysis. Total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and glucose (Glu) were measured by enzymatic methods. Plasma insulin (INS) was measured by chemiluminescence immunoassay. The protein levels of apoA1 and apoB were measured by the turbidimetric immunoassay.
RESULTS: Allele frequencies of G and A were 0.718 and 0.282 in the GDM group and 0.713 and 0.287 in the control group, respectively. Distribution of the genotype frequencies was found to be in Hardy-Weinberg equilibrium in both the GDM and control groups. There was no significant difference in the frequencies of alleles G and A and the genotypes of apoA1 -75 G/A polymorphism between the GDM and the control group (P>0.05). In the GDM group, the carriers with the genotype AA were associated with significantly higher levels of TC, HDL-C, and apoA1 than those with genotypes GG and GA did (all P<0.05). After the GDM patients were divided into obese and non-obese subgroups, the genotype-related apoA1 variation was observed only in obese patients, while the genotype-related TC and HDL-C variations were evident in non-obese patients (P<0.05). In the control group, carriers of genotypes AA and GA had higher systolic blood pressure (SBP) and HDL-C than the carriers of genotype GG did (all P<0.05). Carriers of genotypes AA had significantly lower Glu levels than carriers of genotypes GG and GA did (P<0.05). The control subjects were further divided into subgroups according to their body mass index (BMI). Analysis of the subgroups showed that AA carriers were associated with higher SBP levels in the obese control women only, while lower Glu levels were evident in both obese and non-obese control women.
CONCLUSION: These results suggest that -75 G/A polymorphism in the apoA1 gene is not associated with GDM. However, the genetic variation is closed associated with the plasma apoA1, HDL-C, and TC levels in GDM patients and plasma HDL-C, Glu, and SBP levels in the control subjects. The apoA1 variant-associated lipids and SBP variation is BMI dependent in both groups.
The present invention relates to an external-use medicine for treating psoriasis, which is characterized in that the medicine is prepared from the following raw materials according to the volume ratio: 4 to 6 of scorched earth, 1 of sulfur and 1/10 of pricklyash peel shell. The medicine is made of oil extracted after the raw materials are heated and distilled and/or powder after the oil is extracted. The present invention has the characteristics of simple recipe, simple manufacture, strong sterilization capacity and obvious effect. The present invention has 100% curative ratio on various kinds of itching psoriasis. Psoriasis does not relapse after being healed; the affected skin has no scars, and the medicine has no side effect. The present invention is an external remedy and is used one time each day. Patients affected by psoriasis for 30 years can be healed in one month after using the medicine for 5 to 6 times.
PURPOSE:To obtain an alloy enabling the use of a gypsum burying material, free from Be harmful to the human body, and having satisfactory mechanical properties by adding Zr to an Ni-Cr alloy in place of Be and increasing the Mo content. CONSTITUTION:This alloy consists of, by weight, 15-20% Cr, 8.5-15% Mo, 1-5% Al, 2-7% Mn, 0.3-2.0% Zr and the balance Ni with impurities. Mo has an effect of making the crystal grains fine and strengthening the alloy matrix. Since the mechanical properties are deteriorated by adding Zr, in case of less than the lower limit of Mo, satisfactory mechanical properties are not obtd., yet more than the upper limit of Mo makes the alloy brittle. When the alloy is cast in a gypsum burying material, Zr produces an effect of preventing the surface roughening of the casting. In case of less than the lower limit of Zr, the effect is insufficient, yet more than the upper limit of Zr deteriorates the mechanical properties.